reply from Tarquin22 Nov 2018 15:16
Many thanks for your note below and interest in both ValiRx and ValiSeek and your request for more information on current progress concerning the compound VAL401.
As you should be aware, material news or updates concerning ValiRx or any of its compounds in development, are communicated to all investors via the Regulatory News Service (“RNS”) as soon as that information is available.
Furthermore, in light of the new Market Abuse Regulation (“MAR”) rules, we are limited in what we can communicate directly to private investors.
To discuss in more depth the Company and it’s merits, can I suggest that you ask your broker to get in touch with ValiRx’s broker, Novum Securities, (whose website is: https://novumsecurities.com) and to relay your queries that way.
Hope that helps.
With warmest regards
Tarquin
Tarquin Edwards
Head of Investor relations & Communications
tarquin.edwards@valiRx.com
Mobile: +44 (0) 7879 458 364
null
UK Registered Office:
ValiRx Plc, 3rd Floor, 16 Upper Woburn Place, London, WC1H 0BS
Website: www.valiRx.com
Office Tel: +44 (0) 203 008 4416
The information in this Internet e-mail is confidential and may be legally privileged. It is intended solely for the addressee. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. If you have received this e-mail and you are not a named addressee, please delete it from your system and contact the IT department. Furthermore, the contents of any attachment to this e-mail may contain software viruses that could damage your computer system. While we have taken reasonable precautions to minimise this risk, we shall not accept liability for any damage which you sustain as a result of such software viruses. You should prudently carry out your own virus screening checks before opening any attachments. This message is provided for informational purposes and should not be construed as a solicitation or offer to buy or sell any securities or related financial instruments. In compliance with General Data Protection Regulation, ValiRx plc follows best practise, its privacy policy can be found at: https://www.valirx.com/about-us/privacy-and-gdpr/
Please consider the environment before printing this email
Sent from my iPhone.